Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma

Gupta, M; Stukalin, I; Meyers, D; Goutam, S; Heng, DYC; Cheng, T; Monzon, J; Navani, V

Gupta, M (通讯作者),TomBaker Canc Ctr, Dept Oncol, 1331 29th St NW, Calgary, AB T2N 4N2, Canada.

JAMA NETWORK OPEN, 2023; 6 (6):

Abstract

IMPORTANCE Treatment-free survival (TFS) represents an alternative time-to-event end point, accurately characterizing time spent free of systemic ther......

Full Text Link